In June 2021, Sun Pharma entered into a settlement with Celgene Corporation (Celgene) to resolve the patent litigation regarding its generic lenalidomide capsules. Under the terms of this settlement, Celgene granted Sun Pharma a license to patents required to manufacture and sell certain limited quantities of generic lenalidomide capsules in the US, beginning sometime after March 2022.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MZA4GWr
via IFTTT
0 comments:
Post a Comment